Cero Therapeutics posted a Q2 net loss of USD 1.03 million, narrowing 81% from the prior-year quarter.
Operating loss improved 18.6% to USD 3.85 million as operating expenses fell 18.6% to USD 3.85 million.
Research and development costs dropped 37% to USD 1.74 million, while general and administrative expense rose 7.1% to USD 2.11 million.
Other income swung to USD 2.82 million, driven by a USD 6.61 million gain on reevaluation of preferred stock liabilities.
Cash, restricted cash, and cash equivalents totaled USD 937,512 at June 30, 2026; the company cited substantial doubt about going concern within one year.
CERO•
